Association Between Copy Number Variation of Complement Component C4 and Graves' Disease

Yu-Huei Liu,Lei Wan,Chwen-Tzuei Chang,Wen-Ling Liao,Wen-Chi Chen,Yuhsin Tsai,Chang-Hai Tsai,Fuu-Jen Tsai
DOI: https://doi.org/10.1186/1423-0127-18-71
2011-01-01
Journal of Biomedical Science
Abstract:Background Gene copy number of complement component C4 , which varies among individuals, may determine the intrinsic strength of the classical complement pathway. Presuming a major role of complement as an effecter in peptide-mediated inflammation and phagocytosis, we hypothesized that C4 genetic diversity may partially explain the development of Graves' disease (GD) and the variation in its outcomes. Methods A case-control study including 624 patients with GD and 160 healthy individuals were enrolled. CNV of C4 isotypes ( C4A and C4B ) genes were performed by quantitative real-time polymerase chain reaction analysis. Statistical comparison and identification of CNV of total C4, C4 isotypes ( C4A and C4B ) and C4 polymorphisms were estimated according to the occurrence of GD and its associated clinical features. Results Individuals with 4, 2, and 2 copies of C4 , C4A and C4B genes, especially those with A2B2 polymorphism may associate with the development of GD (p = 0.001, OR = 10.994, 95% CI: 6.277-19.255; p = 0.008, OR = 1.732, 95% CI: 1.190-2.520; p = 2.420 × 10-5, OR = 2.621, 95% CI: 1.791-3.835; and p = 1.395 × 10 -4 , OR = 2.671, 95% CI: 1.761-4.052, respectively). Although the distribution of copy number for total C4 , C4 isotypes as well as C4 polymorphisms did not associate with the occurrence of goiter, nodular hyperplasia, GO and myxedema, <2 copies of C4A may associate with high risk toward vitiligo in patients with GD ( p = 0.001, OR = 5.579, 95% CI: 1.659-18.763). Conclusions These results may be further estimated for its clinical application on GD and the vitiligo in patients with GD.
What problem does this paper attempt to address?